IGF2: an endocrine hormone to improve islet transplant survival
Date
2014
Authors
Hughes, A.
Rojas-Canales, D.
Drogemuller, C.
Voelcker, N.
Grey, S.
Coates, P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Endocrinology, 2014; 221(2):R41-R48
Statement of Responsibility
Amy Hughes, Darling Rojas-Canales, Chris Drogemuller, Nicolas H Voelcker, Shane T Grey and P T H Coates
Conference Name
Abstract
In the week following pancreatic islet transplantation, up to 50% of transplanted islets are lost due to apoptotic cell death triggered by hypoxic and pro-inflammatory cytokine-mediated cell stress. Thus, therapeutic approaches designed to protect islet cells from apoptosis could significantly improve islet transplant success. IGF2 is an anti-apoptotic endocrine protein that inhibits apoptotic cell death through the mitochondrial (intrinsic pathway) or via antagonising activation of pro-inflammatory cytokine signalling (extrinsic pathway), in doing so IGF2 has emerged as a promising therapeutic molecule to improve islet survival in the immediate post-transplant period. The development of novel biomaterials coated with IGF2 is a promising strategy to achieve this. This review examines the mechanisms mediating islet cell apoptosis in the peri- and post-transplant period and aims to identify the utility of IGF2 to promote islet survival and enhance long-term insulin independence rates within the setting of clinical islet transplantation.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2014 Society for Endocrinology